Cara Therapeutics, Inc. (CARA) |
|
1.68 -0.01 (-0.59%)
|
09-29 16:00 |
|
Open: |
1.69 |
Pre. Close: |
1.69 |
|
High:
|
1.735 |
Low:
|
1.67 |
|
Volume:
|
411,719 |
Market Cap:
|
91(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:27 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.79  One year: 3.36 |
| Support: |
Support1: 1.59 Support2: 1.32 |
| Resistance: |
Resistance1: 2.38 Resistance2: 2.88 |
| Pivot: |
1.82 |
| Moving Average: |
MA(5): 1.71 MA(20): 1.89
MA(100): 2.93 MA(250): 6.57 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 9.7 %D(3): 12.1 |
| RSI: |
RSI(14): 34.7 |
| 52-week: |
High: 12.81 Low: 1.59 |
| Average Vol(K): |
3-Month: 753 (K) 10-Days: 627 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CARA ] has closed above bottom band by 29.8%. Bollinger Bands are 14.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.74 - 1.75 |
1.75 - 1.75 |
|
Low:
|
1.65 - 1.66 |
1.66 - 1.67 |
|
Close:
|
1.67 - 1.68 |
1.68 - 1.69 |
|
Company Description |
|
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. |
Headline News |
Fri, 29 Sep 2023
Is it Time to Dump Cara Therapeutics Inc (CARA) Stock After it Is Up 1.20% in a Week? - InvestorsObserver
Tue, 26 Sep 2023
Global Chronic Pruritus Therapeutics Market Size, Share, Forecast 2021 - 2030 | Top key players : AbbVie Inc. - openPR
Mon, 25 Sep 2023
Cara Therapeutics Announces Approval of KORSUVA® IV Injection ... - BioSpace
Wed, 20 Sep 2023
Cara Therapeutics Inc (CARA) Stock: What Does the Chart Say Wednesday? - InvestorsObserver
Mon, 18 Sep 2023
Healthcare Stocks Moving Monday: AVGR, SQL, CABA, SIEN, CARA, MBOT, PIII, LZAGY - InvestorsObserver
Fri, 15 Sep 2023
Healthcare Stocks Moving Friday: OBIO, IOVA, CARA, SLNO, PTCT, PIII, AMAM, HITI - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
54 (M) |
| Shares Float |
38 (M) |
|
% Held by Insiders
|
14.7 (%) |
|
% Held by Institutions
|
64.6 (%) |
|
Shares Short
|
1,550 (K) |
|
Shares Short P.Month
|
3,470 (K) |
Stock Financials |
|
EPS
|
-2 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.01 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-423.8 |
|
Return on Assets (ttm)
|
-39.9 |
|
Return on Equity (ttm)
|
-71.3 |
|
Qtrly Rev. Growth
|
-70 |
|
Gross Profit (p.s.)
|
-1.04 |
|
Sales Per Share
|
0.5 |
|
EBITDA (p.s.)
|
-2.13 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-104 (M) |
|
Levered Free Cash Flow
|
-62 (M) |
Stock Valuations |
|
PE Ratio
|
-0.85 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.83 |
|
Price to Sales
|
3.34 |
|
Price to Cash Flow
|
-0.88 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
